$141MSeries B, 3 November 2025
Funds proof-of-concept clinical studies of AAVB-039 for Stargardt disease and AAVB-081 for Usher 1B retinitis pigmentosa.
- Amount
- $141M
- Stage
- Series B
- Announced
- 3 November 2025
- Lead
- Schroders Capital
- Other investors
- Forbion, Atlas Venture, Amgen Ventures, Athos Capital, CDP Venture Capital, Columbia IMC, Neva SGR, Sixty Degree Capital, XGen Venture, Willett Advisors, Longwood Fund
- Use of funds
- Funds proof-of-concept clinical studies of AAVB-039 for Stargardt disease and AAVB-081 for Usher 1B retinitis pigmentosa.
- Checked
- Announced by the company
- Sources
- Italian biotech AAVantgarde adds 141 million dollar Series B to fund retinal gene therapy trials biospace.com
Italian biotech AAVantgarde adds 141 million dollar Series B to fund retinal gene therapy trials fiercebiotech.com